ストックスクリーナーアプリを入手
0.00
100.00%
-5.00
アフターアワーズ：
5.00
5.00
+
前日終値:
$5.00
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$266.14M
収益：
$44.12M
当期純損益:
$-156.25M
株価収益率:
0.00
EPS:
-3.07
ネットキャッシュフロー:
$-154.61M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
TSVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
0.00 | 266.14M | 44.12M | -156.25M | -154.61M | -3.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-06 | ダウングレード | Goldman | Neutral → Sell |
| 2024-01-31 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-13 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-05-02 | 開始されました | Goldman | Buy |
| 2022-02-10 | 開始されました | SVB Leerink | Outperform |
| 2022-01-06 | 開始されました | Cowen | Outperform |
| 2021-11-09 | 開始されました | Canaccord Genuity | Buy |
| 2021-11-08 | 開始されました | Morgan Stanley | Overweight |
| 2021-11-08 | 開始されました | Wedbush | Outperform |
すべてを表示
2 Seventy Bio Inc (TSVT) 最新ニュース
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades - Managed Healthcare Executive
Cigna Launches AI Tools to Simplify Health Insurance, Improve Customer Experience - Managed Healthcare Executive
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC - Managed Healthcare Executive
Alachua bio-manufacturing plant to lay off employees ahead of shutdown - WCJB | TV20
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
Wellington Management Group LLP Reduces Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
BNP Paribas Financial Markets Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Deutsche Bank AG Has $1.10 Million Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
MHE Week in Review –Medicaid Bill Mayhem, UnitedHealth’s Stock Plummets and More - Managed Healthcare Executive
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Investor relations - Bristol Myers Squibb
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio completes merger with Bristol-Myers Squibb - Investing.com
Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Stelara Biosimilar Yesintek Gains Coverage on Leading Formularies - Managed Healthcare Executive
Yearly Depression Screening for Young Adults Is Worth the Cost - Managed Healthcare Executive
Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $5.60 - Defense World
Updated: UnitedHealth Group’s First Quarter Revenue Increases, But Company Revises Outlook - Managed Healthcare Executive
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc.TSVT - Business Wire
Neuroscientific to Acquire Leading Stem Cell Technology - Investing News Network
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Liver Injury Ends Development of Pfizer’s Oral GLP-1 for Obesity - Managed Healthcare Executive
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
FDA Approves Biocon’s Avastin Biosimilar - Managed Healthcare Executive
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Intech Investment Management LLC - The AM Reporter
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
FDA Approves Cabometyx to Treat Advanced Pancreatic Cancer - Managed Healthcare Executive
Nonopioid Pain Drug Journavx Gaining Traction With High Potential - Managed Healthcare Executive
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies - Managed Healthcare Executive
FDA Approves Novartis’ Oral Fabhalta as First Treatment for C3G - Managed Healthcare Executive
Should MAHA Tackle the Chronic Disease Epidemic with Preventative Care? - Managed Healthcare Executive
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
For Pfizer, Some Challengers in ATTR-CM Treatment - Managed Healthcare Executive
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available - Managed Healthcare Executive
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children - Managed Healthcare Executive
Second Biosimilar of Stelara Launches - Managed Healthcare Executive
FDA Approves First Biosimilar of Novolog - Managed Healthcare Executive
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar - Managed Healthcare Executive
FDA Approves Second Biosimilars for Prolia/Xgeva - Managed Healthcare Executive
2 Seventy Bio Inc (TSVT) 財務データ
収益
当期純利益
現金流量
EPS
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):